Source:http://linkedlifedata.com/resource/pubmed/id/16628262
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-4-21
|
pubmed:abstractText |
Interleukin-23 (IL-23) is a heterodimeric cytokine that is composed of a p40 subunit, shared with the closely related cytokine IL-12, and a smaller IL-23p19 subunit. It belongs to a family of heterodimeric cytokines that also includes IL-12 and IL-27. Experimental autoimmune encephalomyelitis (EAE) is an autoimmune disease that serves as a model for multiple sclerosis, an inflammatory demyelinating disease of the central nervous system that is a frequent cause of disability in young adults. EAE is thought to be initiated by CD4+ T cells. The production of interferon-gamma and tumor necrosis factor-alpha (T helper 1 [Th1] phenotype) was considered a marker for the ability of such cells to induce disease. Consistent with this view, IL-12, a cytokine that induces the differentiation of Th1 cells, was considered essential for EAE susceptibility. However, it is now clear that IL-23 rather than IL-12 is required for EAE susceptibility. IL-23 induces a population of IL-17-producing cells that is more critically involved in EAE pathogenesis than Th1 cells. Here, we review the role of the IL-23 system in the pathophysiology of EAE.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/IL23A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Il23a protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-17,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-23,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-23 Subunit p19,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0214-0934
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2006 Prous Science
|
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
77-83
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16628262-Animals,
pubmed-meshheading:16628262-Central Nervous System,
pubmed-meshheading:16628262-Cytokines,
pubmed-meshheading:16628262-Encephalomyelitis, Autoimmune, Experimental,
pubmed-meshheading:16628262-Humans,
pubmed-meshheading:16628262-Interleukin-17,
pubmed-meshheading:16628262-Interleukin-23,
pubmed-meshheading:16628262-Interleukin-23 Subunit p19,
pubmed-meshheading:16628262-Interleukins,
pubmed-meshheading:16628262-Mice,
pubmed-meshheading:16628262-Multiple Sclerosis,
pubmed-meshheading:16628262-Receptors, Interleukin,
pubmed-meshheading:16628262-Th1 Cells
|
pubmed:year |
2006
|
pubmed:articleTitle |
Pathophysiology of interleukin-23 in experimental autoimmune encephalomyelitis.
|
pubmed:affiliation |
Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|